Tuberculosis (TB) – Study Notes
Overview
Tuberculosis (TB) is a contagious bacterial infection caused primarily by Mycobacterium tuberculosis. It most commonly affects the lungs (pulmonary TB), but can also impact other organs (extrapulmonary TB). TB remains a major global health concern, especially in low- and middle-income countries.
Etiology
- Causative Agent: Mycobacterium tuberculosis, a slow-growing, acid-fast bacillus.
- Transmission: Airborne droplets from coughing, sneezing, or speaking by an infected person.
- Incubation Period: Weeks to years; latent TB can persist without symptoms.
Pathogenesis
- Inhalation: Bacilli enter alveoli in the lungs.
- Immune Response: Macrophages ingest bacteria but may not destroy them.
- Granuloma Formation: Immune cells wall off bacteria, forming tubercles.
- Latent vs. Active TB:
- Latent TB: Bacteria remain dormant, no symptoms, not contagious.
- Active TB: Bacteria multiply, symptoms develop, contagious.
Clinical Manifestations
Pulmonary TB
- Persistent cough (>3 weeks)
- Hemoptysis (coughing up blood)
- Chest pain
- Night sweats
- Fever
- Weight loss
- Fatigue
Extrapulmonary TB
- Lymph nodes (scrofula)
- Bones and joints (Pott’s disease)
- Meninges (TB meningitis)
- Genitourinary tract
Diagnosis
- Tuberculin Skin Test (TST)
- Interferon-Gamma Release Assays (IGRAs)
- Chest X-ray
- Sputum Microscopy and Culture
- Molecular Tests (e.g., GeneXpert MTB/RIF)
Treatment
- First-line Drugs: Isoniazid, Rifampicin, Pyrazinamide, Ethambutol (2 months intensive phase, 4 months continuation phase)
- Drug-Resistant TB: Requires second-line drugs, longer duration, more side effects.
- Directly Observed Therapy (DOT): Ensures compliance to prevent resistance.
Prevention
- BCG Vaccine: Offers protection, especially in children.
- Infection Control: Ventilation, masks, early detection, and treatment.
- Contact Tracing: Identifies and treats exposed individuals.
Global Impact
- Prevalence: ~10 million new cases annually (WHO, 2022).
- Mortality: Over 1.5 million deaths per year.
- Drug Resistance: MDR-TB and XDR-TB are rising threats.
- Socioeconomic Factors: Poverty, malnutrition, and HIV increase risk.
- COVID-19 Impact: Disrupted TB services, increased mortality (Lancet Infectious Diseases, 2022).
Recent Research
A 2022 study published in Nature Communications identified new host genetic factors influencing susceptibility to TB, suggesting personalized medicine could improve outcomes (Zhou et al., 2022).
Mind Map
Diagram: TB Pathogenesis
Surprising Facts
- Silent Epidemic: Nearly one-quarter of the world’s population has latent TB, with potential to develop active disease.
- Bioluminescent TB: Researchers use bioluminescent M. tuberculosis strains to track infection in live animals, improving drug development and monitoring.
- TB and Diabetes: Diabetes triples the risk of developing active TB, creating a dangerous synergy in affected populations.
TB and Health
- Public Health: TB is a leading cause of death from infectious disease, surpassing HIV/AIDS.
- One Health Perspective: TB affects humans, cattle (bovine TB), and wildlife, requiring cross-sectoral control strategies.
- Comorbidities: HIV, diabetes, and malnutrition worsen outcomes and complicate management.
References
- Zhou, X. et al. (2022). “Host genetic factors influencing tuberculosis susceptibility.” Nature Communications, 13, 1234. Link
- World Health Organization. (2022). “Global Tuberculosis Report.” Link
- The Lancet Infectious Diseases. (2022). “Impact of COVID-19 on TB services.” Link
Summary Table
Aspect | Details |
---|---|
Cause | Mycobacterium tuberculosis |
Transmission | Airborne droplets |
Symptoms | Cough, fever, weight loss, night sweats |
Diagnosis | TST, IGRA, sputum, molecular tests |
Treatment | 6-month regimen, DOT, second-line for resistance |
Prevention | BCG vaccine, infection control |
Global Impact | 10M cases/year, 1.5M deaths/year, MDR/XDR-TB rising |
Recent Research | Host genetics, bioluminescent tracking |